Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma
Status:
Recruiting
Trial end date:
2023-09-16
Target enrollment:
Participant gender:
Summary
This study is a open-lable, , single center, phase II clinical study. Target population is
patients with locally resectable osteosarcoma. Study objective is to compare the efficacy and
safety of camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate
in study population in China. Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.